MCL1 and hematologic disorder: Interestingly, in a clinical trial against relapsed or refractory hematological malignancies, some MCL1 inhibitors were reported to promote on-target/off-tumor toxicity, and in that trial, administration of the MCL1 inhibitor AMG-397 was suspended due to cardiac side effects [35].